Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

4.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.0K
Hematopoiesis01:21

Hematopoiesis

9.4K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
9.4K
Lineage Commitment01:21

Lineage Commitment

4.5K
Commitment is the  process whereby stem cells:
4.5K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K
Combinatorial Gene Control02:33

Combinatorial Gene Control

9.8K
Combinatorial gene control is the synergistic action of several transcriptional factors to regulate the expression of a single gene. The absence of one or more of these factors may lead to a significant difference in the level of gene expression or repression.
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
9.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration.

Blood·2026
Same author

Polycomb repressive complex 2 insufficiency underlies myeloid leukemia in Down syndrome.

Blood·2026
Same author

Non-necroptotic MLKL function damages mitochondria and promotes hematopoietic stem cell aging.

Nature communications·2026
Same author

cGAS-IFN-I responses by extracting nuclear DNA from dying cells via nucleocytosis.

Nature communications·2026
Same author

Polycomb repressive complexes as therapeutic targets in hematologic malignancies.

Experimental hematology·2025
Same author

Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome.

Nature communications·2025
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Video

Updated: Mar 2, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.5K

Polycomb repressive complexes in hematological malignancies.

Atsushi Iwama1

  • 1Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.

Blood
|May 10, 2017
PubMed
Summary
This summary is machine-generated.

Deregulation of polycomb repressive complexes (PRCs) impacts hematological malignancies, acting as oncogenic or tumor-suppressive factors. Targeting PRCs offers promising new therapeutic strategies for improving patient outcomes.

More Related Videos

Retroviral Infection of Murine Embryonic Stem Cell Derived Embryoid Body Cells for Analysis of Hematopoietic Differentiation
11:40

Retroviral Infection of Murine Embryonic Stem Cell Derived Embryoid Body Cells for Analysis of Hematopoietic Differentiation

Published on: October 20, 2014

8.9K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

10.1K

Related Experiment Videos

Last Updated: Mar 2, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.5K
Retroviral Infection of Murine Embryonic Stem Cell Derived Embryoid Body Cells for Analysis of Hematopoietic Differentiation
11:40

Retroviral Infection of Murine Embryonic Stem Cell Derived Embryoid Body Cells for Analysis of Hematopoietic Differentiation

Published on: October 20, 2014

8.9K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

10.1K

Area of Science:

  • Epigenetics
  • Hematology
  • Oncology

Background:

  • Polycomb repressive complexes (PRCs) play a critical role in gene regulation.
  • PRC deregulation is implicated in the development of various hematological malignancies.
  • Their function can be oncogenic or tumor-suppressive, varying by cancer type.

Purpose of the Study:

  • To review the role of PRC deregulation in hematological malignancies.
  • To highlight the impact of epigenome alterations in cancer.
  • To discuss the therapeutic potential of targeting PRCs.

Main Methods:

  • Literature review and synthesis of existing research.
  • Analysis of the dual role of PRCs in different hematological cancers.
  • Examination of current clinical studies on PRC-targeted therapies.

Main Results:

  • PRC deregulation is a common feature in hematological malignancies.
  • Epigenetic dysregulation significantly contributes to tumor development and progression.
  • Targeting PRCs shows therapeutic promise in preclinical and clinical settings.

Conclusions:

  • Understanding PRC function in hematological malignancies is crucial for pathophysiology.
  • Therapeutic strategies targeting PRCs are emerging as a novel approach.
  • These strategies hold the potential to improve treatment outcomes for patients.